Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas

E. Gaudio, C. Tarantelli, I. Kwee, C. Barassi, E. Bernasconi, A. Rinaldi, M. Ponzoni, L. Cascione, A. Targa, A. Stathis, S. Goodstal, E. Zucca, F. Bertoni

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Lymphomas are among the most common human cancers and represent the cause of death for still too many patients. The B-cell receptor with its downstream signaling pathways represents an important therapeutic target for B-cell lymphomas. Here, we evaluated the activity of the MEK1/2 inhibitor pimasertib as single agent and in combination with other targeted drugs in lymphoma preclinical models. Materials and methods: Cell lines derived mature B-cell lymphomas were exposed to increasing doses of pimasertib alone. Immunoblotting and gene expression profiling were performed. Combination of pimasertib with idelalisib or ibrutinib was assessed. Results: Pimasertib as single agent exerted a dose-dependent antitumor activity across a panel of 23 lymphoma cell lines, although at concentrations higher than reported for solid tumors. Strong synergism was observed with pimasertib combined with the PI3K inhibitor idelalisib and the BTK inhibitor ibrutinib in cell lines derived from diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma. The data were confirmed in an in vivo experiment treating DLBCL xenografts with pimasertib and ibrutinib. Conclusion: The data presented here provide the basis for further investigation of regimens including pimasertib in relapsed and refractory lymphomas.

Original languageEnglish
Article numbermdw131
Pages (from-to)1123-1128
Number of pages6
JournalAnnals of Oncology
Volume27
Issue number6
DOIs
Publication statusPublished - Jun 18 2016

Fingerprint

Mitogen-Activated Protein Kinase Kinases
Phosphatidylinositol 3-Kinases
Lymphoma
B-Cell Lymphoma
Cell Line
B-Lymphocytes
Mantle-Cell Lymphoma
Lymphoma, Large B-Cell, Diffuse
Gene Expression Profiling
N-(2,3-dihydroxypropyl)-1-((2-fluoro-4-iodophenyl)amino)isonicotinamide
Immunoblotting
Heterografts
Cause of Death
Neoplasms
Pharmaceutical Preparations
PCI 32765

Keywords

  • Diffuse large B-cell lymphoma
  • Ibrutinib
  • Idelalisib
  • Mantle cell lymphoma

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Gaudio, E., Tarantelli, C., Kwee, I., Barassi, C., Bernasconi, E., Rinaldi, A., ... Bertoni, F. (2016). Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas. Annals of Oncology, 27(6), 1123-1128. [mdw131]. https://doi.org/10.1093/annonc/mdw131

Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas. / Gaudio, E.; Tarantelli, C.; Kwee, I.; Barassi, C.; Bernasconi, E.; Rinaldi, A.; Ponzoni, M.; Cascione, L.; Targa, A.; Stathis, A.; Goodstal, S.; Zucca, E.; Bertoni, F.

In: Annals of Oncology, Vol. 27, No. 6, mdw131, 18.06.2016, p. 1123-1128.

Research output: Contribution to journalArticle

Gaudio, E, Tarantelli, C, Kwee, I, Barassi, C, Bernasconi, E, Rinaldi, A, Ponzoni, M, Cascione, L, Targa, A, Stathis, A, Goodstal, S, Zucca, E & Bertoni, F 2016, 'Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas', Annals of Oncology, vol. 27, no. 6, mdw131, pp. 1123-1128. https://doi.org/10.1093/annonc/mdw131
Gaudio, E. ; Tarantelli, C. ; Kwee, I. ; Barassi, C. ; Bernasconi, E. ; Rinaldi, A. ; Ponzoni, M. ; Cascione, L. ; Targa, A. ; Stathis, A. ; Goodstal, S. ; Zucca, E. ; Bertoni, F. / Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas. In: Annals of Oncology. 2016 ; Vol. 27, No. 6. pp. 1123-1128.
@article{88eea76b69c64b6e9ebf06417727eb7a,
title = "Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas",
abstract = "Background: Lymphomas are among the most common human cancers and represent the cause of death for still too many patients. The B-cell receptor with its downstream signaling pathways represents an important therapeutic target for B-cell lymphomas. Here, we evaluated the activity of the MEK1/2 inhibitor pimasertib as single agent and in combination with other targeted drugs in lymphoma preclinical models. Materials and methods: Cell lines derived mature B-cell lymphomas were exposed to increasing doses of pimasertib alone. Immunoblotting and gene expression profiling were performed. Combination of pimasertib with idelalisib or ibrutinib was assessed. Results: Pimasertib as single agent exerted a dose-dependent antitumor activity across a panel of 23 lymphoma cell lines, although at concentrations higher than reported for solid tumors. Strong synergism was observed with pimasertib combined with the PI3K inhibitor idelalisib and the BTK inhibitor ibrutinib in cell lines derived from diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma. The data were confirmed in an in vivo experiment treating DLBCL xenografts with pimasertib and ibrutinib. Conclusion: The data presented here provide the basis for further investigation of regimens including pimasertib in relapsed and refractory lymphomas.",
keywords = "Diffuse large B-cell lymphoma, Ibrutinib, Idelalisib, Mantle cell lymphoma",
author = "E. Gaudio and C. Tarantelli and I. Kwee and C. Barassi and E. Bernasconi and A. Rinaldi and M. Ponzoni and L. Cascione and A. Targa and A. Stathis and S. Goodstal and E. Zucca and F. Bertoni",
year = "2016",
month = "6",
day = "18",
doi = "10.1093/annonc/mdw131",
language = "English",
volume = "27",
pages = "1123--1128",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "6",

}

TY - JOUR

T1 - Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas

AU - Gaudio, E.

AU - Tarantelli, C.

AU - Kwee, I.

AU - Barassi, C.

AU - Bernasconi, E.

AU - Rinaldi, A.

AU - Ponzoni, M.

AU - Cascione, L.

AU - Targa, A.

AU - Stathis, A.

AU - Goodstal, S.

AU - Zucca, E.

AU - Bertoni, F.

PY - 2016/6/18

Y1 - 2016/6/18

N2 - Background: Lymphomas are among the most common human cancers and represent the cause of death for still too many patients. The B-cell receptor with its downstream signaling pathways represents an important therapeutic target for B-cell lymphomas. Here, we evaluated the activity of the MEK1/2 inhibitor pimasertib as single agent and in combination with other targeted drugs in lymphoma preclinical models. Materials and methods: Cell lines derived mature B-cell lymphomas were exposed to increasing doses of pimasertib alone. Immunoblotting and gene expression profiling were performed. Combination of pimasertib with idelalisib or ibrutinib was assessed. Results: Pimasertib as single agent exerted a dose-dependent antitumor activity across a panel of 23 lymphoma cell lines, although at concentrations higher than reported for solid tumors. Strong synergism was observed with pimasertib combined with the PI3K inhibitor idelalisib and the BTK inhibitor ibrutinib in cell lines derived from diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma. The data were confirmed in an in vivo experiment treating DLBCL xenografts with pimasertib and ibrutinib. Conclusion: The data presented here provide the basis for further investigation of regimens including pimasertib in relapsed and refractory lymphomas.

AB - Background: Lymphomas are among the most common human cancers and represent the cause of death for still too many patients. The B-cell receptor with its downstream signaling pathways represents an important therapeutic target for B-cell lymphomas. Here, we evaluated the activity of the MEK1/2 inhibitor pimasertib as single agent and in combination with other targeted drugs in lymphoma preclinical models. Materials and methods: Cell lines derived mature B-cell lymphomas were exposed to increasing doses of pimasertib alone. Immunoblotting and gene expression profiling were performed. Combination of pimasertib with idelalisib or ibrutinib was assessed. Results: Pimasertib as single agent exerted a dose-dependent antitumor activity across a panel of 23 lymphoma cell lines, although at concentrations higher than reported for solid tumors. Strong synergism was observed with pimasertib combined with the PI3K inhibitor idelalisib and the BTK inhibitor ibrutinib in cell lines derived from diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma. The data were confirmed in an in vivo experiment treating DLBCL xenografts with pimasertib and ibrutinib. Conclusion: The data presented here provide the basis for further investigation of regimens including pimasertib in relapsed and refractory lymphomas.

KW - Diffuse large B-cell lymphoma

KW - Ibrutinib

KW - Idelalisib

KW - Mantle cell lymphoma

UR - http://www.scopus.com/inward/record.url?scp=84974851865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84974851865&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdw131

DO - 10.1093/annonc/mdw131

M3 - Article

AN - SCOPUS:84974851865

VL - 27

SP - 1123

EP - 1128

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 6

M1 - mdw131

ER -